

Antonio Pinto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6905572/publications.pdf>

Version: 2024-02-01

14
papers

1,516
citations

933447

10
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

3123
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
2	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	1.6	333
3	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	1.6	277
4	The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. <i>Journal of Pathology</i> , 2010, 221, 248-263.	4.5	231
5	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021, 137, 637-645.	1.4	69
6	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
7	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	1.6	34
8	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
9	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	5.2	21
10	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824.	1.4	21
11	Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. <i>Journal of Translational Medicine</i> , 2021, 19, 489.	4.4	7
12	Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab. <i>Infectious Agents and Cancer</i> , 2021, 16, 38.	2.6	6
13	Childhood Therapy-Related Acute Myeloid Leukemia with t(16;21)(q24;q22)/RUNX1-CBFA2T3 After a Primitive Neuroectodermal Tumor of the Chest Wall. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e660-e666.	0.4	2
14	Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report. <i>Vaccines</i> , 2022, 10, 1021.	4.4	1